R&D channel feed – Endpoints News

R&D channel feed

Merck falls short in PhIII Covid-19 prophylaxis trial, joining Pfizer

3 years ago

Cancer biotech ends trial, searches for sale or other route

3 years ago

Bridge Biotherapeutics' ulcerative colitis drug fails Phase II trial; biotech plans to push forward

3 years ago

En route to BLA filing, Actinium details PhIII win for targeted radiotherapy in acute myeloid leukemia

3 years ago

Astellas' menopause drug hit by FDA delay after spending $97M on a priority review voucher

3 years ago

FDA and HHS should improve institutional review board inspection practices, GAO says

3 years ago

FDA accepts Iveric Bio's NDA, grants priority review for GA drug

3 years ago

Merck seeks more approvals for infectious disease drug

3 years ago

Third Rock-backed autoimmune biotech turns off the lights

3 years ago

Moderna boasts 'step forward' with PhIII data on flu vaccine, but analysts are not so sure

3 years ago

Updated: Pfizer drops half of participants from Lyme trial after saying research contractor broke rules

3 years ago

Putting a twist on targeted therapy, Vor Biopharma heralds proof of concept for its gene-edited stem cells

3 years ago

Applied Therapeutics showcases early data in PhIII rare sugar disease trial

3 years ago

Pfizer gives interim update on PARP inhibitor combo treatment, earns priority review at FDA

3 years ago

Flagship company teams up with Charles River for AI drug discovery

3 years ago

Talaris discontinues two trials, cuts staff and starts ‘strategic alternatives’ search

3 years ago

Merck hands Swedish biotech €10M cash to develop anti-inflammatory drugs

3 years ago

Drug prices 'not justified' by pharma R&D spending, new study says

3 years ago

Biogen CEO says company 'lost its way,' cuts $125M MS partnership amid declining revenue

3 years ago

AlloVir unwraps PhII data of cell therapy in expanded transplant indication, leaves trial plans up in the air

3 years ago

FDA to review Galera’s drug for radiotherapy complication, biotech immediately seeks $30M

3 years ago

Updated: J&J returns rights to early-stage, RNAi NASH candidate to Arrowhead

3 years ago

Cullinan Oncology drops $25M upfront for candidate from Harbour

3 years ago

With a year full of readouts ahead, Disc Medicine secures cash from Bain Capital

3 years ago

First page Previous page 96 97 9899100 101 102 Next page Last page